Clinical OMICS

MAR-APR 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 6 of 51 March/April 2019 Clinical OMICs 5 News GWAS Reveals Hundreds of Genes, Variants Linked to Depression The results of a genome-wide meta-analy- is of genetic data from more than individ- uals has linked 102 genetic variants and 269 genes with depression, and found associations between the psychiatric dis- order and a number of behavioral traits. The researchers, headed by a team at the University of Edinburgh, say their study results offer new insights into the genetic basis of depression, and could lead to new treatment approaches. "These findings are further evidence that depression is partly down to our genetics," commented lead investigator Andrew McIntosh, Ph.D., professor of bi- ological psychiatry and a senior clinical research fellow at the University of Edin- burgh Centre for Clinical Brain Sciences. The international team, including sci- entists in the U.K., Europe, the U.S., and Australia, reported the findings in Nature Neuroscience. n Irish CRO ICON Acquires MolecularMD Pharmaceutical, biotech, and medical de- vice contract research organization (CRO) ICON, based in Dublin, Ireland announced in its year-end earnings statement that it has acquired molecular diagnostics and research laboratory company Molecu- larMD. The deal, whose terms were not disclosed, provides ICON with sig- nificant reach into the area of pre- cision medicine research and the breadth of drug-diagnostic co-de- velopment. ICON, founded in 1990, has a global reach, operating central lab- oratories at its home base in Dub- lin, with additional labs in Farming- dale, NY; Singapore; and Tianjin, China. It also runs a bioanalytical laboratory in Whitesboro, NY. With the acquisition of Portland, OR-based Molec- ularMD, ICON expands its capabilities into molecular diagnostics and gains valuable expertise in the areas of next-generation sequencing (NGS) and immunohisto- chemistry (IHC) testing. n AI Genomics Company Emedgene Raises $6M Automated genetic interpretation platform Emedgene has raised $6 million in a financing round led by OliveTree ventures. The company's goal is to leverage artificial intelligence (AI) to scale genetics-based clinical care. The company's platform leverages AI, which has learned to perform genomics research, while the Emedgene workbench crawls hundreds of online resources to continuously up- date its database to ensure it provides information based on the most recent research and learnings. It also performs automatic conflict resolution to provide the information using a single ontology. "Genetic medicine will inevitably become the medical standard of care, if we can re- move the hurdles to wider adoption," said Emedgene CEO Einat Metzer. "Emedgene does just that, with AI that can surface scientific knowledge in clinical settings, so that every patient has access to the best possible care." n soberv / DigitalVision Vectors / Getty Images Eekhoff Picture Lab / Getty Images MF3d / E+ / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2019